Athens – October 27, 2026 -- Month 6 interim data comparing single-dose Cecolin 9 with Gardasil 9 were presented at the 38th Annual Conference of the International Papillomavirus Society (IPVS 2026), while final results from the Phase III SHINE I study are not expected until 2028.
Navrongo researcher presents Month 6 analysis of PATH's SHINE I study
Dr. Nana A. Ansah of Ghana's Navrongo Health Research Centre presented the interim analysis of PATH's Single-dose HPV Immunobridging Study with New Vaccines (SHINE I; CVIA 104). The Phase III, double-blind, randomized, multinational study runs in Ghana and the Philippines. It compares the immunogenicity and safety of single-dose Cecolin 9, developed by Xiamen Innovax Biotech Co., Ltd. (IX), with Gardasil 9.
Participants include girls aged 9–14 and young women aged 15–20.
IX hosts Booth 14 under the "Together Against HPV" theme in Athens
The conference ran from October 22 to 25. At Booth 14, IX held discussions on vaccine innovation, scientific evidence, accessibility and international collaboration. An interactive signature board and message wall collected attendees' commitments to HPV prevention.
IX's portfolio spans WHO-prequalified Cecolin and China-launched Cecolin 9
Cecolin is IX's WHO-prequalified bivalent HPV vaccine. Cecolin 9, its next-generation 9-valent vaccine, launched in China in 2025. Both rest on the company's proprietary E. coli-derived virus-like particle (VLP) technology platform.
IX states that it is pursuing technology transfer and local capacity building to strengthen sustainable vaccine supply.